CFO Resigns; CEO/Chairman Assumes Dual Financial Role Amidst Ongoing Distress

summarizeSummary

Burzynski Research Institute announced the resignation of its CFO and Secretary, with President and Chairman Stanislaw R. Burzynski assuming the principal financial officer role, consolidating leadership amidst ongoing financial challenges and an FDA clinical hold.

check_boxKey Events

• Chief Financial Officer Resigns

  Patryk P. Goscianski resigned as Chief Financial Officer and Secretary of the company, effective April 17, 2026. The company stated his resignation was not due to any disagreement.

• CEO/Chairman Assumes Dual Role

  Stanislaw R. Burzynski, the current President, Chairman of the Board, and principal executive officer, was appointed to also serve as Chief Financial Officer and Secretary, effective April 17, 2026.

• No Additional Compensation for Dual Role

  Dr. Burzynski will not receive any additional compensation in connection with his appointment as CFO and Secretary.

• Consolidation of Leadership and Governance Concerns

  Dr. Burzynski is the controlling stockholder, involved in significant related-party agreements, and his children are the other two board members, further concentrating control within the family amidst the company's existing financial and regulatory challenges.

auto_awesomeAnalysis

The departure of the Chief Financial Officer, even if stated as amicable, is a significant event for a company already facing a "going concern" warning and an FDA clinical hold. The subsequent appointment of Stanislaw R. Burzynski, who already serves as President, Chairman, and controlling stockholder, to the CFO position centralizes power and raises corporate governance concerns. This move, where the principal executive officer also becomes the principal financial officer, could signal difficulty in attracting independent financial leadership or a strategic decision to consolidate control within the family, especially given Dr. Burzynski's extensive related-party agreements and family ties on the board. Investors should monitor how this leadership structure impacts the company's ability to address its financial and regulatory challenges.